BioSyent Inc. (RX) Analysts See $0.07 EPS

May 18, 2018 - By Julie Dion

Analysts expect BioSyent Inc. (CVE:RX) to report $0.07 EPS on May, 24.They anticipate $0.01 EPS change or 16.67 % from last quarter’s $0.06 EPS. V_RX’s profit would be $1.01 million giving it 36.25 P/E if the $0.07 EPS is correct. After having $0.10 EPS previously, BioSyent Inc.’s analysts see -30.00 % EPS growth. The stock increased 0.40% or $0.04 during the last trading session, reaching $10.15. About 700 shares traded. BioSyent Inc. (CVE:RX) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company has market cap of $147.13 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer. It has a 28.19 P/E ratio. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.